Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

Journal Articles

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Shuji Ozaki, MD PhD, Takeshi Harada, MD PhD, Kengo Udaka, MD, Etsuko Sekimoto, MD PhD, Hironobu Shibata, MD PhD, Toshio Shigekiyo, MD PhD, Hikaru Yagi, MD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Masahiro Oura, MD, Shiro Fujii, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2018-99-115818

Published: 2018

Journal Articles

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Hirokazu Miki, MD PhD, Takeshi Harada, MD PhD, Qu Cui, MD PhD, Asuka Oda, Ariunzaya Bat-Erdene, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Ryohei Sumitani, MD, Munenori Uemura, MD, Mamiko Takahashi, MD, Masami Iwasa, MD, Shiro Fujii, MD, Jumpei Teramachi, DDS, PhD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Masahiro Abe, MD PhD

Blood (2016) 128 (22): 2107.

https://doi.org/10.1182/blood.V128.22.2107.2107

Published: 2016

Journal Articles

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Jumpei Teramachi, DDS, PhD, Masahiro Hiasa, PhD DDS, Asuka Oda, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Takeshi Harada, MDPhD, Derek Hanson, Keiichiro Watanabe, DDS, PhD, Shiro Fujii, MD, Kumiko Kagawa, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Itsuro Endo, MD PhD, Shuji Ozaki, MD PhD, Toshio Matsumoto, MD PhD, Masahiro Abe, MD PhD

Blood (2015) 126 (23): 4203.

https://doi.org/10.1182/blood.V126.23.4203.4203

Published: 2015

Journal Articles

Targeting Myeloma Cells and Their Progenitors By Pim Kinase Inhibition

Shiro Fujii, MD, Hirokazu Miki, MD PhD, Asuka Oda, PhD, Keiichiro Watanabe, DDS, Ryota Amachi, DDS, Hikaru Yagi, MD, Kimiko Sogabe, MD, Mamiko Takahashi, MD, Tomoko Maruhashi, MD, Kengo Udaka, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, Toshio Matsumoto, MD PhD, Masahiro Abe

Blood (2014) 124 (21): 5724.

https://doi.org/10.1182/blood.V124.21.5724.5724

Published: 2014

Journal Articles

Robust Induction Of Th1-Like γδ T Cells With Anti-Myeloma Activity By Lenalidomide In Combination With HMB-PP As Well As Zoledronic Acid

Takeshi Harada, MD, Qu Cui, MD, PhD, Shingen Nakamura, MD, PhD, Hirokazu Miki, MD, PhD, Asuka Oda, PhD, Ryota Amachi, DDS, Masami Iwasa, MD, Kengo Udaka, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, PhD, Shuji Ozaki, MD, PhD, Yoshimasa Tanaka, MD, PhD, Toshio Matsumoto, MD, PhD, Masahiro Abe, MD, PhD

Blood (2013) 122 (21): 129.

https://doi.org/10.1182/blood.V122.21.129.129

Published: 2013

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition

Shiro Fujii, MD, Masami Iwasa, MD, Takeshi Harada, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, PhD, Ryota Amachi, DDS, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Shuji Ozaki, MD, PhD, Toshio Matsumoto, MD, PhD, Masahiro Abe, MD, PhD

Blood (2012) 120 (21): 5011.

https://doi.org/10.1182/blood.V120.21.5011.5011

Published: 2012

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Hiroe Amou, PhD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 1833.

https://doi.org/10.1182/blood.V118.21.1833.1833

Published: 2011

Journal Articles

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Hirokazu Miki, MD, Masahiro Abe, MD, PhD, Kumiko Kagawa, MD, Asuka Oda, PhD, Hiroe Amou, PhD, Akishige Ikegame, PhD, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ayako Nakano, MD, PhD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Yukimasa Shiotsu, PhD, Masaki Ri, MD, Shinsuke Iida, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 5104.

https://doi.org/10.1182/blood.V118.21.5104.5104

Published: 2011

Journal Articles

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Ayako Nakano, MD, PhD, Masahiro Abe, MD, PhD, Daisuke Tsuji, PhD, Hirokazu Miki, MD, Akishige Ikegame, PhD, Shingen Nakamura, MD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Kohji Itoh, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 135.

https://doi.org/10.1182/blood.V118.21.135.135

Published: 2011

Journal Articles

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Keiichiro Watanabe, DDS, Masahiro Abe, MD, PhD, Qu Cui, MD, Makoto Kawatani, PhD, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Tadashi Jinno, MD, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Eiji Tanaka, DDS, PhD, Hiroyuki Osada, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 454.

https://doi.org/10.1182/blood.V116.21.454.454

Published: 2010

Journal Articles

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Qu Cui, MD, Masahiro Abe, MD, PhD, Hirokazu Miki, MD, Shingen Nakamura, MD, Keiichiro Watanabe, DDS, Akishige Ikegame, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 3025.

https://doi.org/10.1182/blood.V116.21.3025.3025

Published: 2010

Journal Articles

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

Hirokazu Miki, MD, Shuji Ozaki, MD, Osamu Tanaka, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ai Mihara, MD, Kumiko Kagawa, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Toshio Matsumoto, MD

Blood (2007) 110 (11): 4783.

https://doi.org/10.1182/blood.V110.11.4783.4783

Published: 2007

NARROW

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Targeting Myeloma Cells and Their Progenitors By Pim Kinase Inhibition

Robust Induction Of Th1-Like γδ T Cells With Anti-Myeloma Activity By Lenalidomide In Combination With HMB-PP As Well As Zoledronic Acid

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only